Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 8/20 | 1.00 |
| ▸ | GSK3B | P49841 | 9/20 | 0.80 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.80 |
| ▸ | CDK2 | P24941 | 6/20 | 0.80 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.80 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.80 |
| ▸ | GSK3A | P49840 | 4/20 | 0.80 |
| ▸ | CLK2 | P49760 | 4/20 | 0.80 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.80 |
| ▸ | PRKACA | P17612 | 3/20 | 0.80 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.80 |
| ▸ | BRSK1 | Q8TDC3 | 2/20 | 0.80 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.80 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.80 |
| ▸ | PRKX | P51817 | 1/20 | 0.80 |
| ▸ | PIM1 | P11309 | 5/20 | 0.68 |
| ▸ | SGK2 | Q9HBY8 | 3/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665724 | 0.89 | ROCK2 (1.00) | ROCK2AURKBGSK3BDYRK1ACDK2 | |
| SCHEMBL12297936 | 0.82 | KDM4E (0.70) | ROCK2AURKBGSK3BDYRK1ACDK2 | |
| SCHEMBL3668478 | 0.81 | AURKB (1.00) | ROCK2AURKBGSK3BDYRK1ACDK2 | |
| SCHEMBL3637752 | 0.80 | ROCK2 (1.00) | ROCK2AURKBGSK3BDYRK1ACDK2 | |
| SCHEMBL12297576 | 0.79 | GAA (0.82) | ROCK2AURKBROCK1MAPK1KDM4E | |
| Fanetizole SCHEMBL1813401 | 0.79 | GAA (0.86) | ROCK2AURKBROCK1MAPK1KDM4E | |
| Fanetizole SCHEMBL11365554 | 0.78 | GAA (0.84) | ROCK2AURKBROCK1MAPK1KDM4E | |
| SCHEMBL12297836 | 0.78 | KDM4E (0.67) | ROCK2AURKBGSK3BDYRK1ACDK2 | |
| SCHEMBL12297577 | 0.76 | KDM4E (0.76) | ROCK2AURKBROCK1MAPK1KDM4E | |
| SCHEMBL12297921 | 0.74 | SMN1; SMN2 (0.66) | ROCK2AURKBMAPK1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | claimed |
| CN-101790526-A | 5-heteroaryl substituted indazoles as kinase inhibitors | ABBOTT GMBH & CO KG | 2010-07-28 | — | — | CN | claimed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| CN-101790526-A | 5-heteroaryl substituted indazoles as kinase inhibitors | ABBOTT GMBH & CO KG | 2010-07-28 | — | — | CN | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885AURKB 125/4885GSK3B 1/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885AURKB 125/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.